Brief: Allakos Announces Initiation Of Phase 2B Clinical Trial Of Subcutaneous Lirentelimab In Chronic Spontaneous Urticaria (CSU)
12/09/2022 12:14
Sept 12 (Reuters) - Allakos Inc ALLK.O :
* ALLAKOS ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF
SUBCUTANEOUS LIRENTELIMAB IN CHRONIC SPONTANEOUS URTICARIA (CSU)
* TOP-LINE RESULTS FROM TRIAL ARE EXPECTED IN SECOND HALF OF
2023
Source text for Eikon: ID:nGNX4VB9Jx
Further company coverage: ALLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allakos
See all newsAllakos Inc reports results for the quarter ended March 31 - Earnings Summary
Allakos Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group
Allakos soars on buyout deal with Concentra Biosciences
Brief: Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences